Detailed Information on Publication Record
2023
Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data.
WEINBERGEROVÁ, Barbora, M. ČERŇAN, Tomáš SZOTKOWSKI, Lukáš SEMERÁD, T. KABUT et. al.Basic information
Original name
Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data.
Name (in English)
Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data
Authors
WEINBERGEROVÁ, Barbora (203 Czech Republic, belonging to the institution), M. ČERŇAN (203 Czech Republic), Tomáš SZOTKOWSKI (203 Czech Republic), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), T. KABUT (203 Czech Republic), J. NAVRÁTILOVÁ (203 Czech Republic), N. PODSTAVKOVÁ (203 Czech Republic), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Iveta KLEMEŠOVÁ (203 Czech Republic), A. FOLTA (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes, 2023
Other information
Language
Czech
Type of outcome
Konferenční abstrakt
Field of Study
30205 Hematology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/23:00131059
Organization unit
Faculty of Medicine
Keywords in English
Gemtuzumab ozogamicin; Midostaurin; AML
Tags
Změněno: 13/3/2024 08:54, Mgr. Tereza Miškechová
V originále
Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data - konferenční abstrakt.
In English
Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data - conference abstract.
Links
| LX22NPO5102, research and development project |
|